 Outlook Therapeutics Inc NASDAQ:OTLK said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United States of its ONS-5010 treatment for wet age-related macular degeneration AMD. ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. 